Main menu

NEW YORK (GenomeWeb) – T2 Biosystems today preliminarily reported a 50 percent increase year over year in product revenue growth for the fourth quarter of 2016.

The Lexington, Massachusetts-based diagnostics firm attributed the growth to an increase in T2Candida Panel sales associated with increased patient testing across the installed base. The firm also secured eight new contracts covering 18 hospitals in the US and Europe and has increased its worldwide installed base to include 143 hospitals with access to T2Dx Instruments.